Nativis Research Partner to Present at COGNO Conference in Australia

Nativis Publishes Proof of Concept Paper Using Voyager™ System to Inhibit Enzyme in Algae

Study suggests potential for increased output for bio-fuel and other algae-related products

Nativis, Inc., a clinical stage life science bio-electronic company developing non-invasive, safe and highly effective treatments for cancers and other serious diseases, announced the use of the same technology to inhibit a key enzyme in algae. The paper entitled “Non-Thermal Radio Frequency Stimulation Inhibits the Tryptophan Synthase Beta Subunit in the Alga Chlamydomonas reinhardtii” presented proof of concept data demonstrating the ability of the Nativis signal transduction technology to increase algae survival by altering specific enzyme levels in Chlamydomonas reinhardtii.

Upon receiving the results of this research, Chris Rivera, Nativis President and CEO said, “we are very excited to have the first proof of concept work show the Voyager™ system technology can be adapted to inhibit the synthesis of the enzyme tryptophan synthase beta subunit (MAA7) by applying an electro-magnetic-field (EMF) with our ulRFE technology derived from a published siRNA. The results of this research have encouraged us to continue with further investigation to explore and identify other key enzymes that regulate lipid production (increasing lipids to make more oil) and the commercial viability of this technology.” Rivera continued with the observation that, “This could also lead to tailoring proteins from algae resulting in greater concentration for feedstock and other uses, all without using any chemical interactions.”

Regarding the commercial viability of this technology, Michael Mischke-Reeds, Nativis Senior Vice President for Business Development observed, “there are over 30 major companies worldwide that are operating in the algae sector. Out of those companies, about one-third are actively engaged in biofuel production. The leading companies in this fast-growing sector (e.g., Dow Chemical, Fuji Chemical, Syngulon), are growing algae for cosmetics, nutraceuticals, and/or feed stock. Products include omega-3, omega-7, astaxanthin, beta-carotene, lutein, zeaxanthin and beta-cryptoxanthin. So, you can see the market potential of our technology if we can significantly increase efficiency of algae production with minimal impact on cost. Other applications of the Nativis technology are in health maintenance of algae (by inhibiting infective agents), thus reducing costs of treatment or loss of whole ponds.”

The paper may be reviewed at

About Nativis, Inc.
Founded in 2002 and headquartered in Seattle, WA, Nativis is a clinical-stage bio-electronics company. Nativis has invented and patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulRFE) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use non-invasive device called Nativis Voyager®. The company’s goal is to transform disease treatment on a global scale with ulRFE that can potentially be applied to a wide range of conditions and other health-related needs (including agriculture, bio-fuels and veterinary medicine, to name a few). Nativis’ initial focus is on the treatment of patients with brain cancer (initially, recurrent glioblastoma), who are not well served by conventional standard of care therapies, which often result in poor outcomes and devastating side effects. Additional pre-clinical work is being completed for melanoma, lung cancer, liver cancer, inflammatory disease and chronic pain.

Investor Relations Contact:
Lee Roth / Tram Bui /
646-536-7012 / 7035

Media Relations Contact:
Aaron Blank / Amber Benson /

Back to News